COLUMBUS, Ohio – The National Cancer Institute (NCI) has awarded a five-year, $11.3 million grant to a team of researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to further their studies on thyroid cancer.
Principal investigator Matthew D. Ringel, MD, professor of medicine and a member of the OSUCCC – James Molecular Biology and Cancer Genetics (MBCG) Program, leads the NCI Program Project Grant (CA124570). The new grant is a continuation of a study that ran from 2008 through 2013 entitled "Genetic and Signaling Pathways in Epithelial Thyroid Cancer."
The study has four integrated projects:
In addition, the Program Project Grant funds three shared-resource cores:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 228-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S.News & World Report.